



TREATMENT AND MANAGEMENT OF CHRONIC CSCR

- Good medical history to rule out steroid use
- Steroid hormone antagonists (i.e. eplerenone (Inspra))
- Half fluence PDT
- Sleep study to r/o apnea
- FA/ICG to evaluate for CNVM for anti-VEGF (i.e. Avastin)




CASE #2


- Brief case history
- 25 yo male presents w/ h/o MVA 1 week ago c/o "black smudge" in vision
 Entrance acuity 20/20 OD, OS
- Amsler: Multiple paracentral scotomas in both eyes
- Fundus findings:
 - OD & OS: parafoveal deep greyish lesions




CLINICAL PEARLS FOR AMN


- Acute paracentral scotomas corresponding to retinal lesion.
- Visual changes may be acute transient or permanent.
- Outer retinal structures are affected.
- - Type 1 AMN: may be caused by ischemia of the superficial capillary plexus (INL/OPL)
 - Type 2 AMN: may be caused by ischemic insult to the deep capillary plexus (ONL/OPL)


















































































































REFERENCES

- Acute Macular Neuroretinopathy Associated with Systemic Lupus Eyithematosus: Lupus (2016) 25, 431-435.
 Acute Macular Neuroretinopathy in Dengue Fever Short-term Prospectively Followed Up Case Series; JAMA ophthalmic (2015):133(11):1292-1333.
 Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: Ophthalmology (2016) 123, 578-588.

- Amenyas.cuair credimental crowth Factor Agens in the treatment of Retinal Disease. Ophthalmology (2016) 123, 378-889.

 Clinical Endpoints for the Study of Geographic Alrophy Secondary to Age-Related Macular Degeneration: Retina (2016) 336, 1806-1822.

 Electronic Medical Record Databases Study of Vitrectomy and Observation for Vitreomacular Traction: Retina (2016) 36, 1897-1905.

 Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Efficacy and Safety Outcomes Intelled Protodiagnoss and Photodynamic Therapy (2016) 14, 173-177.

 Long-term Outcomes of Intravitreal Bevacizumab Therapy for Subretinal Neovascularization Secondary to Idiopathic Macular Telangiectasia Type 2: Retina (2016) 36, 2150-2157.

 New Associations of Classic Acute Macular Neuroretinopathy. Br J Ophthalmic (2016) 100, 389-394.

 Optical Coherence Tomographic Anglography in Central Serous Chorioretinopathy: Retina (2016) 36, 2051-2058.

REFERENCES

- Peripheral Exudative Hemorrhagic Chorioretinopathy, Polypoidal Choroidal Vasculopathy and Hemodynamic Modifications. Am. J Ophthalmology (2012) 910-922.

 Quantifying Visual Dysfunction and the Response to Surgery in Macular Pucker. Ophthalmology (2016) 123, 1500-1510.

 Recovery of Foveal Photoreceptor Integrity after Vitrectomy in Eyes with an Impending Macular Hole with Vitreomacular fraction Syndrome. Retina (2016) 36, 1454-1462.

 Results of the 2-year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized faila (Ophthalmology (2016) 123, 2232-2247.

 The Pathogenesis of Early Retinal Changes of Diabetic Retinopathy, Doc Ophthalmol (2012) 124, 15-26.

